Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center

[1] Kurina LM(2001)Depression and anxiety in people with inflammatory bowel disease J Epidemiol Community Health 55 716-720

[2] Gionchetti P(2017)3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations J Crohns Colitis 11 135-149

[3] Dignass A(2017)Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management J Crohns Colitis 11 769-784

[4] Danese S(2016)Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease—algorithm for practical management Aliment Pharmacol Ther 43 30-51

[5] Harbord M(2013)Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases Eur J Int Med 24 385-392

[6] Eliakim R(2012)Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry Am J Gastroenterol 107 1409-1422

[7] Bettenworth D(2013)Vedolizumab as induction and maintenance therapy for Crohn’s disease N Engl J Med 369 711-721

[8] Ding NS(2013)Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 699-710

[9] Hart A(2016)The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US Victory Consortium Am J Gastroenterol 111 1147-1155

[10] De Cruz P(2018)Vedolizumab for ulcerative colitis: treatment outcomes from the Victory Consortium Am J Gastroenterol 113 1345-1354

[1] Kurina LM(2001)Depression and anxiety in people with inflammatory bowel disease J Epidemiol Community Health 55 716-720

[2] Gionchetti P(2017)3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations J Crohns Colitis 11 135-149

[3] Dignass A(2017)Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management J Crohns Colitis 11 769-784

[4] Danese S(2016)Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease—algorithm for practical management Aliment Pharmacol Ther 43 30-51

[5] Harbord M(2013)Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases Eur J Int Med 24 385-392

[6] Eliakim R(2012)Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry Am J Gastroenterol 107 1409-1422

[7] Bettenworth D(2013)Vedolizumab as induction and maintenance therapy for Crohn’s disease N Engl J Med 369 711-721

[8] Ding NS(2013)Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 699-710

[9] Hart A(2016)The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US Victory Consortium Am J Gastroenterol 111 1147-1155

[10] De Cruz P(2018)Vedolizumab for ulcerative colitis: treatment outcomes from the Victory Consortium Am J Gastroenterol 113 1345-1354